The History of Biomarkers How Far Have We Come?

被引:1
|
作者
Lachmann, Gunnar [1 ,2 ,3 ,4 ,5 ]
Reinhart, Konrad [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Charite Univ Med Berlin, CVK, Dept Anesthesiol & Operat Intens Care Med CCM, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Humboldt Univ, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Berlin Inst Hlth, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Berlin Inst Hlth, Anna Louisa Karsch Str 2, D-10178 Berlin, Germany
[6] Jena Univ Hosp, Carl Zeiss Str 12, D-07743 Jena, Germany
关键词
Sepsis; Biomarker; History; INTERNATIONAL CONSENSUS DEFINITIONS; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; SEVERE SEPSIS; SEPTIC SHOCK; FRAGMENT AFELIMOMAB; PROCALCITONIN; INTERLEUKIN-6; DYSFUNCTION; NEUTROPHILS; EFFICACY;
D O I
10.1016/j.ccc.2019.08.001
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Sepsis is one of the oldest and most elusive syndromes in medicine that is still incompletely understood. Biomarkers may help to transform sepsis from a physiologic syndrome to a group of distinct biochemical disorders. This will help to differentiate between systemic inflammation of infectious and noninfectious origin and aid therapeutic decision making, hence improve the prognosis for patients, guide antimicrobial therapy, and foster the development of novel adjunctive sepsis therapies. To reach this goal requires increased systematic investigation that includes twenty-first century scientific approaches and technologies and appropriate clinical evaluation.
引用
收藏
页码:1 / +
页数:11
相关论文
共 50 条